deferoxamine (desferal) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.   NCATS

Chemistry

  • SMILES: CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
  • InChIKey: UBQYURCVBFRUQT-UHFFFAOYSA-N
  • Mol. Mass: 560.69
  • ALogP: 0.92
  • ChEMBL Molecules:
    deferoxamine  
    deferoxamine mesylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$10.5000 - $33.4925
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ba-33112 | deferoxamin | deferoxamina | deferoxamine | déferoxamine | deferoxamine hydrochloride | deferoxamine mesilate | deferoxamine mesylate | deferoxaminum | deferrioxamine | deferrioxamine b | desferal | desferal mesylate | desferrioxamine | desferrioxamine mesilate | desferrioxamine mesylate | dfo | dfoa | dfom

Organizations (89)

Research & Development (83)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (34)

Approved Indications (1)


 

Iron Overload (approved 1968)

Experimental Indications - Clinical Trial Phases 1-4 (34)


 

Acute Kidney Injury (Phase 2)

Aging (Early Phase 1)

Anemia (Phase 4)

Anemia, Hemolytic (Phase 2)

Anemia, Iron-Deficiency (Phase 2)

Anemia, Sickle Cell (Phase 4)

Ascorbic Acid (Phase 2/Phase 3)

beta-Thalassemia (Phase 4)

Blood Transfusion (Phase 4)

Carcinoma, Hepatocellular (Phase 1)

Cardiomyopathies (Phase 4)

Cardiovascular Diseases (Phase 2)

Cerebral Hemorrhage (Phase 2)

COVID-19 (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetic Foot (Phase 2)

Heart Diseases (Phase 2)

Hematologic Diseases (Phase 2)

Hemochromatosis (Phase 3)

Hemoglobinopathies (Phase 2)

Hemosiderosis (Phase 4)

Hypotension (Phase 2)

Immune System Diseases (Phase 1)

Intensive Care Units (Phase 3)

Intracranial Aneurysm (Phase 1/Phase 2)

Iron Overload (Phase 4)

Ischemic Stroke (Phase 2)

Neoplasm Metastasis (Phase 1)

Oxidative Stress (Phase 2/Phase 3)

Stroke (Early Phase 1)

Subarachnoid Hemorrhage (Phase 2)

Thalassemia (Phase 4)

Triple Negative Breast Neoplasms (Phase 2)

Ulcer (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial Organizations: 83

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue